Skip to main content
Top
Published in: BMC Nephrology 1/2024

Open Access 01-12-2024 | Acute Kidney Injury | Research

Predictive performance of two types of urinary biomarkers for renal non-recovery in sepsis-associated acute kidney injury: a prospective observational study

Authors: Licheng, Huimiao Jia, Yijia Jiang, Wenxiong Li

Published in: BMC Nephrology | Issue 1/2024

Login to get access

Abstract

Background and purpose

Renal non-recovery is known to have negative prognostic implications in patients suffering from acute kidney injury (AKI). Nevertheless, the identification of biomarkers for predicting renal non-recovery in sepsis-associated AKI (SA-AKI) within clinical settings remains unresolved. This study aims to evaluate and compare the predictive ability for renal non-recovery, use of kidney replacement therapy (KRT) in the Intensive Care Unit (ICU), and 30-day mortality after SA-AKI by two urinary biomarkers, namely C-C motif chemokine ligand 14 (CCL14) and [TIMP-2]•[IGFBP7].

Methods

We prospectively screened adult patients who met the criteria for AKI stage 2–3 and Sepsis-3.0 in two ICUs from January 2019 to May 2022. Patients who developed new-onset SA-AKI after ICU admission were enrolled and urinary biomarkers including [TIMP-2]•[IGFBP7] and CCL14 were detected at the time of SA-AKI diagnosis. The primary endpoint was non-recovery from SA-AKI within 7 days. The secondary endpoints were the use of KRT in the ICU and 30-day mortality after SA-AKI. The individual discriminative ability of [TIMP-2]•[IGFBP7] and CCL14 to predict renal non-recovery were evaluated by the area under receiver operating characteristics curve (AUC).

Results

141 patients with stage 2–3 SA-AKI were finally included, among whom 54 (38.3%) experienced renal non-recovery. Urinary CCL14 exhibited a higher predictive capability for renal non-recovery compared to [TIMP-2]•[IGFBP7], with CCL14 showing an AUC of 0.901, versus an AUC of 0.730 for [TIMP-2]•[IGFBP7] (P = 0.001). Urinary CCL14 and [TIMP-2]•[IGFBP7] demonstrated a moderate predictive value for the need for KRT in ICU, with AUC values of 0.794 and 0.725, respectively; The AUC of [TIMP-2]•[IGFBP7] combined with CCL14 reached up to 0.816. Urinary CCL14 and [TIMP-2]•[IGFBP7] exhibited poor predictive power for 30-day mortality, with respective AUC values of 0.623 and 0.593.

Conclusion

Urinary CCL14 had excellent predictive value for renal non-recovery in SA-AKI patients. For predicting the use of KRT in the ICU, the predictive capability of urinary [TIMP-2]•[IGFBP7] or CCL14 was fair. However, a combination of [TIMP-2]•[IGFBP7] and CCL14 showed good predictive ability for the use of KRT.
Appendix
Available only for authorised users
Literature
3.
go back to reference Huang CY, Güiza F, De Vlieger G, Wouters P, Gunst J, Casaer M. ea ta. Development and validation of clinical prediction models for acute kidney injury recovery at hospital discharge in critically ill adults. J Clin Monit Comput. 2023;37:113–125. Huang CY, Güiza F, De Vlieger G, Wouters P, Gunst J, Casaer M. ea ta. Development and validation of clinical prediction models for acute kidney injury recovery at hospital discharge in critically ill adults. J Clin Monit Comput. 2023;37:113–125.
4.
go back to reference Xia WH, Yi F, Qb W. Mortality and differential predictive factors of transient and persistent sepsis-associated acute kidney injury. Clin Nephrol. 2023;99:119–27.CrossRefPubMed Xia WH, Yi F, Qb W. Mortality and differential predictive factors of transient and persistent sepsis-associated acute kidney injury. Clin Nephrol. 2023;99:119–27.CrossRefPubMed
5.
go back to reference Perinel S, Vincent F, Lautrette A, Dellamonica J, Mariat C, Zeni F, et al. Transient and persistent acute kidney injury and the risk of hospital mortality in critically ill patients. Crit Care Med. 2015;43:e269–275.CrossRefPubMed Perinel S, Vincent F, Lautrette A, Dellamonica J, Mariat C, Zeni F, et al. Transient and persistent acute kidney injury and the risk of hospital mortality in critically ill patients. Crit Care Med. 2015;43:e269–275.CrossRefPubMed
6.
go back to reference Choi JS, Kim YA, Kim MJ, Kang YU, Kim CS, Bae EH, et al. Relation between transient or persistent acute kidney injury and long-term mortality in patients with myocardial infarction. Am J Cardiol. 2013;112:41–5.CrossRefPubMed Choi JS, Kim YA, Kim MJ, Kang YU, Kim CS, Bae EH, et al. Relation between transient or persistent acute kidney injury and long-term mortality in patients with myocardial infarction. Am J Cardiol. 2013;112:41–5.CrossRefPubMed
7.
go back to reference Dellepiane S, Marengo M, Cantaluppi V. Detrimental crosstalk between sepsis and acute kidney injury: new pathogenic mechanisms, early biomarkers and targeted therapies. Crit Care. 2016;20:61.CrossRefPubMedPubMedCentral Dellepiane S, Marengo M, Cantaluppi V. Detrimental crosstalk between sepsis and acute kidney injury: new pathogenic mechanisms, early biomarkers and targeted therapies. Crit Care. 2016;20:61.CrossRefPubMedPubMedCentral
8.
go back to reference Schuler A, Wulf DA, Lu Y, Iwashyna TJ, Escobar GJ, Shah NH, et al. The impact of acute organ dysfunction on long-term survival in Sepsis. Crit Care Med. 2018;46:843–9.CrossRefPubMedPubMedCentral Schuler A, Wulf DA, Lu Y, Iwashyna TJ, Escobar GJ, Shah NH, et al. The impact of acute organ dysfunction on long-term survival in Sepsis. Crit Care Med. 2018;46:843–9.CrossRefPubMedPubMedCentral
9.
go back to reference Emlet DR, Pastor-Soler N, Marciszyn A, Wen XY, Gomez H, Humphries WH 4th, et al. Insulin-like growth factor binding protein 7 and tissue inhibitor of metalloproteinases-2: differential expression and secretion in human kidney tubule cells. Am J Physiol Ren Physiol. 2017;312:F284–96.CrossRef Emlet DR, Pastor-Soler N, Marciszyn A, Wen XY, Gomez H, Humphries WH 4th, et al. Insulin-like growth factor binding protein 7 and tissue inhibitor of metalloproteinases-2: differential expression and secretion in human kidney tubule cells. Am J Physiol Ren Physiol. 2017;312:F284–96.CrossRef
10.
go back to reference Kellum JA, Chawla LS. Cell-cycle arrest and acute kidney injury: the light and the dark sides. Nephrol Dial Transpl. 2016;31:16–22.CrossRef Kellum JA, Chawla LS. Cell-cycle arrest and acute kidney injury: the light and the dark sides. Nephrol Dial Transpl. 2016;31:16–22.CrossRef
11.
go back to reference Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17:R25.CrossRefPubMedPubMedCentral Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17:R25.CrossRefPubMedPubMedCentral
12.
go back to reference Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610–21.CrossRefPubMed Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610–21.CrossRefPubMed
13.
go back to reference Kulvichit W, Kellum JA, Srisawat N. Biomarkers in Acute kidney Injury. Crit Care Clin. 2021;37:385–98.CrossRefPubMed Kulvichit W, Kellum JA, Srisawat N. Biomarkers in Acute kidney Injury. Crit Care Clin. 2021;37:385–98.CrossRefPubMed
14.
go back to reference Hoste E, Bihorac A, Al-Khafaji A, Ortega LM, Ostermann M, Haase M, et al. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study. Intensive Care Med. 2020;46:943–53.CrossRefPubMedPubMedCentral Hoste E, Bihorac A, Al-Khafaji A, Ortega LM, Ostermann M, Haase M, et al. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study. Intensive Care Med. 2020;46:943–53.CrossRefPubMedPubMedCentral
15.
go back to reference Qian BS, Jia HM, Weng YB, Li XC, Chen CD, Guo FX, et al. Analysis of urinary C-C motif chemokine ligand 14 (CCL14) and first-generation urinary biomarkers for predicting renal recovery from acute kidney injury: a prospective exploratory study. J Intensive care. 2023;11:11.CrossRefPubMedPubMedCentral Qian BS, Jia HM, Weng YB, Li XC, Chen CD, Guo FX, et al. Analysis of urinary C-C motif chemokine ligand 14 (CCL14) and first-generation urinary biomarkers for predicting renal recovery from acute kidney injury: a prospective exploratory study. J Intensive care. 2023;11:11.CrossRefPubMedPubMedCentral
16.
go back to reference Tandukar S, Palevsky PM. Continuous renal replacement therapy: who, when, why, and how. Chest. 2019;155:626–38.CrossRefPubMed Tandukar S, Palevsky PM. Continuous renal replacement therapy: who, when, why, and how. Chest. 2019;155:626–38.CrossRefPubMed
17.
18.
go back to reference Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.CrossRefPubMedPubMedCentral Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.CrossRefPubMedPubMedCentral
19.
go back to reference Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care. 2013;17:204.CrossRefPubMedPubMedCentral Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care. 2013;17:204.CrossRefPubMedPubMedCentral
20.
go back to reference Zarbock A, Nadim MK, Pickkers P, Gomez H, Bell S, Joannidis M, et al. Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup. Nat Rev Nephrol. 2023;19:401–17.CrossRefPubMed Zarbock A, Nadim MK, Pickkers P, Gomez H, Bell S, Joannidis M, et al. Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup. Nat Rev Nephrol. 2023;19:401–17.CrossRefPubMed
21.
go back to reference Kellum JA, Sileanu FE, Bihorac A, Hoste EAJ, Chawla LS. Recovery after acute kidney injury. Am J Respir Crit Care Med. 2017;6:784–91.CrossRef Kellum JA, Sileanu FE, Bihorac A, Hoste EAJ, Chawla LS. Recovery after acute kidney injury. Am J Respir Crit Care Med. 2017;6:784–91.CrossRef
22.
23.
go back to reference Gocze I, Koch M, Renner P, Zeman F, Graf BM, Dahlke MH, et al. Urinary biomarker TIMP-2 and IGFBP7 early predict acute kidney Injury after major surgery. PLoS ONE. 2015;10:e0120863.CrossRefPubMedPubMedCentral Gocze I, Koch M, Renner P, Zeman F, Graf BM, Dahlke MH, et al. Urinary biomarker TIMP-2 and IGFBP7 early predict acute kidney Injury after major surgery. PLoS ONE. 2015;10:e0120863.CrossRefPubMedPubMedCentral
24.
go back to reference Ostermann M, Zarbock A, Goldstein S, Kashani K, Macedo E, Murugan R et al. Recommendations on Acute Kidney Injury Biomarkers from the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement. JAMA Netw Open. 2020;3:e2019209. Ostermann M, Zarbock A, Goldstein S, Kashani K, Macedo E, Murugan R et al. Recommendations on Acute Kidney Injury Biomarkers from the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement. JAMA Netw Open. 2020;3:e2019209.
25.
go back to reference Jia HM, Cheng L, Weng YB, Wang JY, Zheng X, Jiang YY, et al. Cell cycle arrest biomarkers for predicting renal recovery from acute kidney injury: a prospective validation study. Ann Intensive Care. 2022;12:14.CrossRefPubMedPubMedCentral Jia HM, Cheng L, Weng YB, Wang JY, Zheng X, Jiang YY, et al. Cell cycle arrest biomarkers for predicting renal recovery from acute kidney injury: a prospective validation study. Ann Intensive Care. 2022;12:14.CrossRefPubMedPubMedCentral
26.
go back to reference Xie Y, Ankawi G, Yang B, Garzotto F, Passannante A, Breglia A, et al. Tissue inhibitor metalloproteinase-2 (TIMP-2)•IGF-binding protein-7 (IGFBP7) levels are associated with adverse outcomes in patients in the intensive care unit with acute kidney injury. Kidney Int. 2019;95:1486–93.CrossRefPubMed Xie Y, Ankawi G, Yang B, Garzotto F, Passannante A, Breglia A, et al. Tissue inhibitor metalloproteinase-2 (TIMP-2)•IGF-binding protein-7 (IGFBP7) levels are associated with adverse outcomes in patients in the intensive care unit with acute kidney injury. Kidney Int. 2019;95:1486–93.CrossRefPubMed
27.
go back to reference Koyner JL, Shaw AD, Chawla LS, Hoste EA, Bihorac A, Kashani K, et al. Tissue inhibitor Metalloproteinase-2 (TIMP-2)•IGF-Binding Protein-7 (IGFBP7) levels are Associated with adverse long-term outcomes in patients with AKI. J Am Soc Nephrol. 2015;26:1747–54.CrossRefPubMed Koyner JL, Shaw AD, Chawla LS, Hoste EA, Bihorac A, Kashani K, et al. Tissue inhibitor Metalloproteinase-2 (TIMP-2)•IGF-Binding Protein-7 (IGFBP7) levels are Associated with adverse long-term outcomes in patients with AKI. J Am Soc Nephrol. 2015;26:1747–54.CrossRefPubMed
28.
go back to reference Godi I, De Rosa S, Martino F, Bazzano S, Martin M, Boni E, et al. Urinary [TIMP-2]×[IGFBP7] and serum procalcitonin to predict and assess the risk for short-term outcomes in septic and non-septic critically ill patients. Ann Intensive Care. 2020;10:46.CrossRefPubMedPubMedCentral Godi I, De Rosa S, Martino F, Bazzano S, Martin M, Boni E, et al. Urinary [TIMP-2]×[IGFBP7] and serum procalcitonin to predict and assess the risk for short-term outcomes in septic and non-septic critically ill patients. Ann Intensive Care. 2020;10:46.CrossRefPubMedPubMedCentral
29.
go back to reference Ninet S, Schnell D, Dewitte A, Zeni F, Meziani F, Darmon M. Doppler-based renal resistive index for prediction of renal dysfunction reversibility: a systematic review and meta-analysis. J Crit Care. 2015;30:629–35.CrossRefPubMed Ninet S, Schnell D, Dewitte A, Zeni F, Meziani F, Darmon M. Doppler-based renal resistive index for prediction of renal dysfunction reversibility: a systematic review and meta-analysis. J Crit Care. 2015;30:629–35.CrossRefPubMed
30.
go back to reference Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol. 2007;2:431–9.CrossRefPubMed Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol. 2007;2:431–9.CrossRefPubMed
31.
go back to reference Peters E, Antonelli M, Wittebole X, Nanchal R, François B, Sakr Y, et al. A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from the Intensive Care Over Nations audit. Crit Care. 2018;22:188.CrossRefPubMedPubMedCentral Peters E, Antonelli M, Wittebole X, Nanchal R, François B, Sakr Y, et al. A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from the Intensive Care Over Nations audit. Crit Care. 2018;22:188.CrossRefPubMedPubMedCentral
32.
go back to reference Zarbock A, Küllmar M, Ostermann M, Lucchese G, Baig K, Cennamo A, Prevention of cardiac surgery-associated acute kidney injury by implementing the KDIGO guidelines in high-risk patients identified by biomarkers: The PrevAKI-Multicenter Randomized Controlled Trial. Anesth Analg., Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP et al. Program to Improve Care in Acute Renal Disease (PICARD) Study Group. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009;76:422–427. Zarbock A, Küllmar M, Ostermann M, Lucchese G, Baig K, Cennamo A, Prevention of cardiac surgery-associated acute kidney injury by implementing the KDIGO guidelines in high-risk patients identified by biomarkers: The PrevAKI-Multicenter Randomized Controlled Trial. Anesth Analg., Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP et al. Program to Improve Care in Acute Renal Disease (PICARD) Study Group. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009;76:422–427.
33.
go back to reference Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Program to Improve Care in Acute Renal Disease (PICARD) Study Group. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009;76:422–427. Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Program to Improve Care in Acute Renal Disease (PICARD) Study Group. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009;76:422–427.
34.
go back to reference Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL. Sepsis occurrence in acutely ill patients (SOAP) investigators. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care. 2008;12:R74.CrossRefPubMedPubMedCentral Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL. Sepsis occurrence in acutely ill patients (SOAP) investigators. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care. 2008;12:R74.CrossRefPubMedPubMedCentral
Metadata
Title
Predictive performance of two types of urinary biomarkers for renal non-recovery in sepsis-associated acute kidney injury: a prospective observational study
Authors
Licheng
Huimiao Jia
Yijia Jiang
Wenxiong Li
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2024
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-024-03589-9

Other articles of this Issue 1/2024

BMC Nephrology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.